BlackRock
CLVS

BlackRock’s Clovis Oncology, Inc. CLVS Stock Holding History

BlackRock’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,035,344
Closed -$4.8M – 5910
2022
Q3 		$4.8M Sell
4,035,344
-686,873
-15% -$1.07M ﹤0.01% 3771
2022
Q2 		$8.5M Sell
4,722,217
-5,263,542
-53% -$7.76M ﹤0.01% 3592
2022
Q1 		$20.2M Buy
9,985,759
+253,189
+3% +$497K ﹤0.01% 3171
2021
Q4 		$26.4M Buy
9,732,570
+237,497
+3% +$878K ﹤0.01% 3108
2021
Q3 		$42.3M Buy
9,495,073
+679,399
+8% +$3.27M ﹤0.01% 2767
2021
Q2 		$51.1M Buy
8,815,674
+996,664
+13% +$5.84M ﹤0.01% 2689
2021
Q1 		$54.9M Buy
7,819,010
+973,203
+14% +$6.53M ﹤0.01% 2553
2020
Q4 		$32.9M Buy
6,845,807
+889,732
+15% +$4.5M ﹤0.01% 2734
2020
Q3 		$34.7M Buy
5,956,075
+332,067
+6% +$1.99M ﹤0.01% 2511
2020
Q2 		$38M Buy
5,624,008
+1,832,171
+48% +$13.9M ﹤0.01% 2411
2020
Q1 		$24.1M Buy
3,791,837
+372,769
+11% +$2.99M ﹤0.01% 2503
2019
Q4 		$35.6M Sell
3,419,068
-1,455,800
-30% -$10.6M ﹤0.01% 2560
2019
Q3 		$19.2M Buy
4,874,868
+325,558
+7% +$2.63M ﹤0.01% 2840
2019
Q2 		$67.6M Buy
4,549,310
+273,464
+6% +$4.94M ﹤0.01% 2151
2019
Q1 		$106M Sell
4,275,846
-74,312
-2% -$1.86M ﹤0.01% 1838
2018
Q4 		$78.1M Buy
4,350,158
+38,218
+0.9% +$781K ﹤0.01% 1972
2018
Q3 		$127M Sell
4,311,940
-17,803
-0.4% -$689K 0.01% 1801
2018
Q2 		$197M Buy
4,329,743
+563,121
+15% +$27.4M 0.01% 1473
2018
Q1 		$199M Buy
3,766,622
+40,263
+1% +$2.35M 0.01% 1369
2017
Q4 		$253M Buy
3,726,359
+129,643
+4% +$9.06M 0.01% 1184
2017
Q3 		$296M Buy
3,596,716
+199,964
+6% +$15.9M 0.02% 1040
2017
Q2 		$318M Buy
3,396,752
+347,042
+11% +$21.2M 0.02% 947
2017
Q1 		$194M Buy
3,049,710
+3,047,145
+118,797% +$185M 0.01% 1324
2016
Q4 		$114K Sell
2,565
-310
-11% -$10.9K ﹤0.01% 2476
2016
Q3 		$103K Buy
2,875
+318
+12% +$6.82K ﹤0.01% 2569
2016
Q2 		$35K Buy
2,557
+742
+41% +$10.8K ﹤0.01% 3085
2016
Q1 		$35K Buy
1,815
+996
+122% +$21.1K ﹤0.01% 2562
2015
Q4 		$29K Sell
819
-62
-7% -$4K ﹤0.01% 2383
2015
Q3 		$80K Buy
881
+245
+39% +$21.2K ﹤0.01% 1781
2015
Q2 		$56K Sell
636
-23
-3% -$1.97K ﹤0.01% 1937
2015
Q1 		$49K Sell
659
-96
-13% -$6.78K ﹤0.01% 1962
2014
Q4 		$42K Hold
755
– – ﹤0.01% 2027
2014
Q3 		$34K Hold
755
– – ﹤0.01% 2103
2014
Q2 		$32K Buy
755
+108
+17% +$5.56K ﹤0.01% 2146
2014
Q1 		$45K Buy
647
+41
+7% +$3.01K ﹤0.01% 1964
2013
Q4 		$36K Buy
606
+41
+7% +$2.23K ﹤0.01% 2057
2013
Q3 		$34K Sell
565
-2,189
-79% -$155K ﹤0.01% 2006
2013
Q2 		$184K Buy
+2,754
New +$124K ﹤0.01% 1519

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

BlackRock's CLVS Position: Q4 2022 in Review

BlackRock sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 4,035,344 shares — an estimated $4.8M sold.

BlackRock first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $318M in Q2 2017. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • BlackRock reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • BlackRock sold 4,035,344 Clovis Oncology, Inc. shares in Q4 2022, an estimated $4.8M.
  • BlackRock first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
  • BlackRock's Clovis Oncology, Inc. position peaked at $318M in Q2 2017.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on BlackRock's 13F filing for Q4 2022, filed 13 Feb 2023.